On Tuesday, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) opened higher 1.64% from the last session, before settling in for the closing price of $8.53. Price fluctuations for AUPH have ranged from $4.71 to $10.67 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 3182.04% annually for the last half of the decade. Company’s average yearly earnings per share was noted 1015.00% at the time writing. With a float of $122.12 million, this company’s outstanding shares have now reached $140.88 million.
In an organization with 130 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 87.99%, operating margin of -0.57%, and the pretax margin is 3.17%.
Aurinia Pharmaceuticals Inc (AUPH) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Aurinia Pharmaceuticals Inc is 11.08%, while institutional ownership is 42.21%. The most recent insider transaction that took place on Mar 07 ’25, was worth 68,350. In this transaction Chief Medical Officer of this company sold 8,305 shares at a rate of $8.23, taking the stock ownership to the 153,484 shares. Before that another transaction happened on Mar 03 ’25, when Company’s Chief Executive Officer sold 195,593 for $8.00, making the entire transaction worth $1,564,744. This insider now owns 1,953,892 shares in total.
Aurinia Pharmaceuticals Inc (AUPH) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1015.00% per share during the next fiscal year.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Trading Performance Indicators
Check out the current performance indicators for Aurinia Pharmaceuticals Inc (AUPH). In the past quarter, the stock posted a quick ratio of 4.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.06. Likewise, its price to free cash flow for the trailing twelve months is 27.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.04, a number that is poised to hit 0.10 in the next quarter and is forecasted to reach 0.75 in one year’s time.
Technical Analysis of Aurinia Pharmaceuticals Inc (AUPH)
Let’s dig in a bit further. During the last 5-days, its volume was 1.13 million. That was inferior than the volume of 1.47 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 88.66%. Additionally, its Average True Range was 0.31.
During the past 100 days, Aurinia Pharmaceuticals Inc’s (AUPH) raw stochastic average was set at 51.46%, which indicates a significant decrease from 94.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.86% in the past 14 days, which was lower than the 46.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.04, while its 200-day Moving Average is $7.30. However, in the short run, Aurinia Pharmaceuticals Inc’s stock first resistance to watch stands at $8.75. Second resistance stands at $8.84. The third major resistance level sits at $8.99. If the price goes on to break the first support level at $8.52, it is likely to go to the next support level at $8.37. The third support level lies at $8.28 if the price breaches the second support level.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Key Stats
There are currently 137,339K shares outstanding in the company with a market cap of 1.19 billion. Presently, the company’s annual sales total 235,130 K according to its annual income of 5,750 K. Last quarter, the company’s sales amounted to 59,870 K and its income totaled 1,430 K.
